History

History

Your molecule, your journey, our mission.

We have strategically invested in and acquired platforms and facilities uniquely designed to enable integrated early-phase development for oral drugs, nanomedicines, and injectables. Each step of the way, we’ve tailored our capabilities to better support our partners on their journey to delivering innovative therapies.

2025

Ardena acquires Catalent site in New Jersey

Ardena expands its global footprint with the acquisition of a state-of-the-art drug product manufacturing facility in Somerset, New Jersey. This addition enhances Ardena’s ability to support clients with end-to-end drug development and manufacturing services while establishing a foundation for future bioanalytical capabilities in North America.

2021

Ardena acquires Idifarma

Idifarma, based in Pamplona, Spain, offers a full range of services spanning the pharma lifecycle from formulation, analytical to manufacturing services for highly potent drugs. Its capabilities include a platform for an accelerated path to clinic and innovating spray drying processes to overcome solubility issues. Established in 2001, Idifarma now has 120 employees.

2020

GHO Capital becomes the new reference shareholder in Ardena

GHO Capital together with management acquires the Ardena Group from Mentha Capital. GHO plans to further strengthen Ardena’s broad service proposition through organic and inorganic opportunities, adding to both the Company’s offering and international footprint.

2018

Ardena acquires Syntagon

Ardena acquires Scandinavian company Syntagon and strengthens its drug substance service offering. Drug substance batch sizes up to 100 kg can be produced. The 30-strong Syntagon team also adds specialist expertise in GMP chromatographic purification processes to our group.

Ardena acquires Chemconnection

Ardena acquires Chemconnection, adding drug substance and nanomedicine expertise. Based at the Pivot Park life sciences campus in Oss, the Netherlands, ChemConnection employs a team of more than 60 with expertise in process and analytical development, cGMP manufacturing and stability studies for Drug Substances and nanomedicines. Its state-of-the-art facility has the capability to manufacture active ingredients up to 30 kg scale.

2017

Launch of the Ardena brand

Ardena is launched as the new brand for our services. The Ardena name reveals the increased service offering and complementary capabilities of the former companies, Pharmavize and Crystallics. Our logo resembles a compass and symbolizes Ardena’s navigational skills. During the drug development journey, we point, with minimized risk, our customers in the best direction.

Ardena acquires ABL

The acquisition of Netherlands based ABL broadens our preclinical and clinical offering to include bioanalytical and drug discovery services. The 60-strong ABL team specializes in the analysis of endogenous (biomarkers) and exogenous compounds (drugs) in biological matrices derived from humans and animals. ABL is active in all phases of drug development, including discovery, pre-clinical and clinical phases.

2016

Acquisition of Crystallics

Netherlands based Crystallics is the first company that joins Pharmavize in executing its vertical integration strategy. Crystallics is specialized in the identification, characterization and selection of the physical forms of drug substances. The company is a pioneer in the field of solid-state research and developed unique and proprietary technologies.

2015

Mentha Capital invests in Pharmavize

Pharmavize, a Belgium based CDMO specialized in drug and dossier development, engages private equity company Mentha Capital and starts executing a M&A strategy to become a leading, one-source and fully integrated contract developer of investigational drugs.

Your molecule, your journey, our mission.

Get in touch to see how we can craft your path to the clinic with dedicated capabilities.

Get in touch